我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

无针注射移植骨髓间充质干细胞治疗缺血性心脏病的实验研究

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第6期
页码:
647-651
栏目:
基础研究
出版日期:
2017-06-01

文章信息/Info

Title:
Experimental study on treatment of ischemic heart disease by delivery of bone marrow mesenchymal stem cells using a needle-free injection model
作者:
吴 奇1; 郑 琴2; 周 鹏1; 金家贵1
（成都医学院第一附属医院：1.心内科，2.老年病科，四川 成都 610500）
Author(s):
WU Qi1;  ZHENG Qin2;  ZHOU Peng1;  JIN Jia-gui1
(1.Department of Cardiology, 2.Department of Geriatric Medicine, First Affiliated Hospital, Chengdu Medical College, Chengdu 610500, Sichuan, China)
关键词:
无射喷射; 骨髓间充质干细胞; 缺血性心脏病
Keywords:
needle-free injection;  bone marrow mesenchymal stem cells;  ischemic heart disease
分类号:
R541.8
DOI:
-
文献标识码:
A
摘要:
目的 探讨无针注射移植骨髓间充质干细胞(BMSCs)治疗缺血性心脏病的可行性。方法 健康杂种犬32只建立急性心梗(MI)模型并随机分为4组为单纯建模组（MI组），无针注射生理盐水组（NS组），有针注射移植干细胞组（N+MSCs组），无针注射移植干细胞组（NF+MSCs组）。术后6周检测血流动力学，处死动物后分离心脏行大体及组织学观察，计算MI面积并行新生血管计数。结果 N+MSCs组及NF+MSCs组梗死区心肌被纤维结缔组织替代，其间可见新生小血管；分别与MI组，NS组及N+MSCs组比较，NF+MSCs组左室舒张末压(9.00±3.2)mmHg(1 mmHg=0.133 kPa)下降、左室内压最大上升(841.86±72.85)mmHg/s和下降速率(-787.29±45.08)mmHg/s升高、梗死面积(18.59±3.58)%缩小、新生小血管数量(9.57±2.23)增多（P<0.05）。结论 无针注射移植干细胞治疗缺血性心脏病是安全，有效的。
Abstract:
AIM To explore the feasibility and effectiveness of treating ischemic heart disease by delivery of bone marrow mesenchymal stem cells (MSCs) using needle-free injection. METHODS Thirty-two dogs were randomly divided into myocardial infarction (MI) group, needle-free injection of normal saline(NS) group, needle injection of mesenchymal stem cells(N+MSCs) group, and needle-free injection of mesenchymal stem cells (N+MSCs) group. Before operation, acute myocardial infarction model was produced by ligation of the left anterior descending coronary artery. No treatment, delivery of normal saline using needle-free injection, delivery of stem cells using needle injection and delivery of stem cells using needle-free injection was completed, respectively. done at the myocardial infarction area in the 4 groups. Hemodynamic monitoring was performed after the 6-week treatment. The hearts were harvested and sectioned for histological and immunohistochemical examination, and the infarct size and the number of small vessels were measured after the animals were sacrificed. RESULTS In group N+MSCs and group NF+MSCs, the infarct area was replaced by fibrous connective tissue and newborn small blood vessels were observed. Compared with other groups, the left ventricular end diastolic pressure (9.00±3.2) mmHg was decreased, the maximum rise rate (841.86±72.85) mmHg/s and the maximum decline rate (-787.29±45.08) mmHg/s of left ventricular pressure were increased, the infarct size (18.59±3.58)% was decreased and the number of newborn small vessels (9.57±2.23) increased in the group with delivery of stem cells using needle-free injection (P<0.05). CONCLUSION It is safe and effective to treat the ischemic heart disease with the needle-free injection of stem cells.

参考文献/References

[1]Mozzafarian D,Benjamin EJ,Go AS,et al.Heart Disease and Stroke Statistics-2016 Update:A Report From the American Heart Association[J].Circulation,2016,133(4):e38-e360.
[2]Levine Gn,Bates Er,Bittl Ja,et al.2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease[J].J Am Coll Cardiol,2016,68(10):1082-1115.
[3]Tanaka Y,Shirasawa B,Takeuchi Y,et al.Autologous preconditioned mesenchymal stem cell sheets improve left ventricular function in a rabbit old myocardial infarction model[J].Am J Transl Res,2016,8(5):2222-2233.
[4]曹 瑞，谭妙欣，孙 勇，等.心脏干细胞治疗心肌梗死的优化策略[J].心脏杂志,2015,27(5):624-628.
[5]Soran O.Alternative Therapy for Medically Refractory Angina:Enhanced External Counterpulsation and Transmyocardial Laser Revascularization[J].Heart Fail Clin,2016,12(1):107-116.
[6]Briones E,Lacalle Jr,Marin-Leon I,et al.Transmyocardial laser revascularization versus medical therapy for refractory angina[J].Cochrane Database Syst Rev,2015(2):CD003712.
[7]吴 奇,黄 晶,李文章.无针喷射心肌打孔给药的实验研究[J].解放军医学杂志,2012,7(37):681-685.
[8]Spiegelstein D,Kim C,Zhang Y,et al.Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival[J].Am J Physiol Heart Circ Physiol,2007,293(6):H3311-H3316.
[9]Freyman T,Polin G,Osman H,et al.A quantitative,randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction[J].Eur Heart J,2006,27(9):1114-1122.
[10]Zhou D,Xiong L,Wu Q,et al.Effects of transmyocardial jet revascularization with chitosan hydrogel on channel patency and angiogenesis in canine infarcted hearts[J].J Biomed Mater Res A,2013,101(2):567-574.
[11]吴 奇,李文章,黄 晶.心肌无针注射的可行性及规律[J].中国老年学杂志,2015,35(4):1004-1006.
[12]沈利水,屈百鸣.骨髓间充质干细胞修复心肌损伤的研究进展[J].心脏杂志,2013,25(5):620-622.
[13]毛洪波,邹 赛,唐俊明,等.间充质干细胞分泌的血管内皮生长因子对心肌细胞的保护作用[J].心脏杂志,2013,25(1):17-21.
[14]Wehman B,Sharma S,Pietris N,et al.Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload[J].Am J Physiol Heart Circ Physiol,2016,310(11):H1816-H1826.
[15]Badimon L,Onate B,Vilahur G. Adipose-derived Mesenchymal Stem Cells and Their Reparative Potential in Ischemic Heart Disease[J].Rev Esp Cardiol(Engl Ed),2015,68(7):599-611.
[16]Hayashi M,Li Ts,Ito H,et al.Comparison of intramyocardial and intravenous routes of delivering bone marrow cells for the treatment of ischemic heart disease:an experimental study[J].Cell Transplant,2004,13(6):639-647.
[17]Perin Ec,Silva Gv,Assad Ja,et al.Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction[J].J Mol Cell Cardiol,2008,44(3):486-495.
[18]Gozdemir M,Demircioglu RI,Karabayirli S,et al.A Needle-Free Injection System(INJEX)with lidocaine for epidural needle insertion:A randomized controlled trial[J].Pak J Med Sci,2016,32(3):756-761.

备注/Memo

备注/Memo:
收稿日期：2016-10-31.基金项目:四川省教育厅基金重点项目资助(15ZA0259)；成都医学院校基金项目资助(CYZ13-011)
作者简介：吴奇，主治医师，博士 Email:wuqi837157@163.com
更新日期/Last Update: 2017-06-06